Skip to main content
. Author manuscript; available in PMC: 2015 Nov 2.
Published in final edited form as: ACS Chem Biol. 2015 Jun 23;10(8):1831–1837. doi: 10.1021/acschembio.5b00442

Figure 4.

Figure 4

A) The enantiomers of HaloPROTACs (containing D-amino acid residues) which do not bind VHL do not induce degradation of GFP-HaloTag7, supporting the necessity of VHL binding for activity. B) Pre-treatment with excess ent-HaloPROTAC3 (1 hour) prevents degradation of GFP-HaloTag7 by HaloPROTAC3 after 24 hours. C) Pre-treatment with epoxomicin (4 hours) prevents degradation of GFP-HaloTag7 by HaloPROTAC3 after 20 hours. D)Treatment with VL285 attenuates the ability of HaloPROTAC3 to induce the degradation of GFP-HaloTag7. E) Structure of VL285. All error bars depict SEM. All compounds were tested in triplicate.